Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
310.9 INR | +3.07% | +3.43% | +24.53% |
05-13 | Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico | MT |
04-30 | Natural Biocon (India) CFO Passes Away | MT |
Sales 2024 * | 145B 1.74B 138B | Sales 2025 * | 166B 1.99B 158B | Capitalization | 371B 4.45B 353B |
---|---|---|---|---|---|
Net income 2024 * | 9.49B 114M 9.04B | Net income 2025 * | 9.3B 111M 8.85B | EV / Sales 2024 * | 3.52 x |
Net Debt 2024 * | 139B 1.67B 133B | Net Debt 2025 * | 143B 1.71B 136B | EV / Sales 2025 * | 3.1 x |
P/E ratio 2024 * |
39.1
x | P/E ratio 2025 * |
43.5
x | Employees | 16,545 |
Yield 2024 * |
0.43% | Yield 2025 * |
0.46% | Free-Float | 37.3% |
Latest transcript on Biocon Limited
1 day | +3.07% | ||
1 week | +3.43% | ||
Current month | +4.14% | ||
1 month | +13.47% | ||
3 months | +16.35% | ||
6 months | +36.75% | ||
Current year | +24.53% |
Managers | Title | Age | Since |
---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 30/04/13 |
Peter Bains
CEO | Chief Executive Officer | 65 | 11/12/22 |
Chairman | 71 | 28/11/78 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 28/11/78 | |
Director/Board Member | 69 | 31/12/99 | |
Director/Board Member | 60 | 26/07/18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.17% | 6 M€ | +6.07% | - |
Date | Price | Change | Volume |
---|---|---|---|
14/05/24 | 310.9 | +3.07% | 7 379 389 |
13/05/24 | 301.6 | -0.77% | 6,333,418 |
10/05/24 | 304 | +1.79% | 9,538,715 |
09/05/24 | 298.6 | -2.72% | 9,996,765 |
08/05/24 | 307 | +4.05% | 9,296,466 |
Delayed Quote NSE India S.E., May 14, 2024 at 12:49 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.53% | 4.31B | |
+4.54% | 111B | |
+11.63% | 105B | |
-12.94% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.07% | 16.96B | |
+3.50% | 13.7B | |
+37.60% | 12.45B |
- Stock Market
- Equities
- BIOCON Stock